Login Register Cart 0
Generic placeholder image

Central Nervous System Agents in Medicinal Chemistry

Editor-in-Chief

ISSN (Print): 1871-5249
ISSN (Online): 1875-6166

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Insight into the Structure and Physicochemical Properties of Potent Chemokine Receptor 5 Inhibitors for the Discovery of Novel Alzheimer’s Disease Drugs

Author(s): Nur Intan Saidaah Mohamed Yusof, Nor Atirah Awaluddin and Fazlin Mohd Fauzi*

Volume 23, Issue 2, 2023

Published on: 01 August, 2023

Page: [95 - 108] Pages: 14

DOI: 10.2174/1871524923666230726102846

Price: $65

conference banner
Abstract

Background: In Alzheimer’s Disease (AD), chemokines recruit pro-inflammatory mediators and increase the aggregation of both Aβ (amyloid-β) plaque and neurofibrillary tangles (NFTs). Chemokine receptor 5 (CCR5) has been demonstrated to be involved in neuroinflammation and neuroimmunology, where its inhibition was shown to enhance memory, plasticity and learning.

Objective: In this study, compounds that inhibit CCR5 obtained from the ChEMBL database were analysed, specifically for whether specific substructures and physicochemical properties are correlated to biological activity.

Methods: Clustering was first performed to group 1,237 compounds into 10 clusters based on the similarities of their structure. Then, molecular docking was performed on 10 compounds representative of each cluster. Lastly, the Spearman correlation was computed between physicochemical properties and biological activity.

Results: Results showed that potent CCR5 inhibitors tend to: (i) be larger in size (molecular weight of more than 500 g/mol), (ii) bind at the deep hydrophobic pocket, mostly through π-π stacking and (iii) have more than 1 aromatic ring. The larger size may aid in reaching the deep hydrophobic pocket. However, these requirements may lead to the violation of more than 1 Lipinski’s Rule of 5.

Conclusion: Future studies should include analyses of the analogues or derivatives of the representative compounds to further expand on the findings here and establish the structure-activity relationship for CCR5 inhibition. This would aid in the development of new AD drugs since drug discovery and development of AD drugs are suffering from high attrition.

« Previous Next »
Graphical Abstract

[1]
Duong S, Patel T, Chang F. Dementia: What pharmacists need to know. Can Pharm J 2017; 150(2): 118-29.
[2]
Quiroz YT, Zetterberg H, Reiman EM. et al. Plasma neurofilament light chain in the presenilin 1 E280A autosomal dominant Alzheimer’s disease kindred: A cross-sectional and longitudinal cohort study. Lancet Neurol 2020; 19(6): 513-21.
[http://dx.doi.org/10.1016/S1474-4422(20)30137-X] [PMID: 32470423]
[3]
Barthélemy NR, Li Y, Joseph-Mathurin N. et al. A soluble phosphorylated tau signature links tau, amyloid and the evolution of stages of dominantly inherited Alzheimer’s disease. Nat Med 2020; 26(3): 398-407.
[http://dx.doi.org/10.1038/s41591-020-0781-z] [PMID: 32161412]
[4]
Braak H, Thal DR, Ghebremedhin E, Del Tredici K. Stages of the pathologic process in Alzheimer disease: Age categories from 1 to 100 years. J Neuropathol Exp Neurol 2011; 70(11): 960-9.
[http://dx.doi.org/10.1097/NEN.0b013e318232a379] [PMID: 22002422]
[5]
Alzheimer’s disease international. World Alzheimer Report 2018. 2021. Available From: https://www.alzint.org/
[6]
2021 Alzheimer’s disease facts and figures. Alzheimers Dement 2021; 17(3): 327-406.
[http://dx.doi.org/10.1002/alz.12328] [PMID: 33756057]
[7]
Sevigny J, Chiao P, Bussière T. et al. The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease. Nature 2016; 537(7618): 50-6.
[http://dx.doi.org/10.1038/nature19323] [PMID: 27582220]
[8]
Larkin HD. Lecanemab gains FDA approval for early Alzheimer disease. JAMA 2023; 329(5): 363.
[http://dx.doi.org/10.1001/jama.2022.24490] [PMID: 36652625]
[9]
Walsh S, Merrick R, Milne R, Brayne C. Aducanumab for Alzheimer’s disease?. United Kingdom: British Medical Journal Publishing Group 2021.
[10]
Tiwari S, Atluri V, Kaushik A, Yndart A, Nair M. Alzheimer’s disease: Pathogenesis, diagnostics, and therapeutics. Int J Nanomedicine 2019; 14: 5541-54.
[http://dx.doi.org/10.2147/IJN.S200490] [PMID: 31410002]
[11]
Fan L, Mao C, Hu X. et al. New insights into the pathogenesis of Alzheimer’s disease. Front Neurol 2020; 10: 1312.
[http://dx.doi.org/10.3389/fneur.2019.01312] [PMID: 31998208]
[12]
Ising C, Heneka MT. Functional and structural damage of neurons by innate immune mechanisms during neurodegeneration. Cell Death Dis 2018; 9(2): 120.
[http://dx.doi.org/10.1038/s41419-017-0153-x] [PMID: 29371603]
[13]
Domingues C, da Cruz E, Silva OAB, Henriques AG, Henriques A. Impact of cytokines and chemokines on Alzheimer’s disease neuropathological hallmarks. Curr Alzheimer Res 2017; 14(8): 870-82.
[PMID: 28317487]
[14]
Walters A, Phillips E, Zheng R, Biju M, Kuruvilla T. Evidence for neuroinflammation in Alzheimer’s disease. Prog Neurol Psychiatry 2016; 20(5): 25-31.
[http://dx.doi.org/10.1002/pnp.444]
[15]
Zuena AR, Casolini P, Lattanzi R, Maftei D. Chemokines in Alzheimer’s disease: New insights into prokineticins, chemokine-like proteins. Front Pharmacol 2019; 10: 622.
[http://dx.doi.org/10.3389/fphar.2019.00622] [PMID: 31231219]
[16]
Sowa JE, Tokarski K. Cellular, synaptic, and network effects of chemokines in the central nervous system and their implications to behavior. Pharmacol Rep 2021; 73(6): 1595-625.
[http://dx.doi.org/10.1007/s43440-021-00323-2] [PMID: 34498203]
[17]
Stone MJ, Hayward JA, Huang CE, Huma Z, Sanchez J. Mechanisms of regulation of the chemokine-receptor network. Int J Mol Sci 2017; 18(2): 342.
[http://dx.doi.org/10.3390/ijms18020342] [PMID: 28178200]
[18]
Jasinska AJ, Pandrea I, Apetrei C. CCR5 as a coreceptor for human immunodeficiency virus and simian immunodeficiency viruses: A prototypic love-hate affair. Front Immunol 2022; 13: 835994.
[http://dx.doi.org/10.3389/fimmu.2022.835994] [PMID: 35154162]
[19]
Joy MT, Assayag EB, Shabashov-Stone D, Liraz-Zaltsman S, Mazzitelli J, Arenas M. et al. CCR5 is a therapeutic target for recovery after stroke and traumatic brain injury. Cell 2019; 176(5): 1143-57.
[http://dx.doi.org/10.1016/j.cell.2019.01.044]
[20]
Scholten DJ, Canals M, Maussang D. et al. Pharmacological modulation of chemokine receptor function. Br J Pharmacol 2012; 165(6): 1617-43.
[http://dx.doi.org/10.1111/j.1476-5381.2011.01551.x] [PMID: 21699506]
[21]
Zhou M, Greenhill S, Huang S. et al. CCR5 is a suppressor for cortical plasticity and hippocampal learning and memory. eLife 2016; 5: e20985.
[http://dx.doi.org/10.7554/eLife.20985] [PMID: 27996938]
[22]
Shen Y, Zhou M, Cai D. et al. CCR5 closes the temporal window for memory linking. Nature 2022; 606(7912): 146-52.
[http://dx.doi.org/10.1038/s41586-022-04783-1] [PMID: 35614219]
[23]
Cummings JL, Goldman DP, Simmons-Stern NR, Ponton E. The costs of developing treatments for Alzheimer’s disease: A retrospective exploration. Alzheimers Dement 2022; 18(3): 469-77.
[http://dx.doi.org/10.1002/alz.12450] [PMID: 34581499]
[24]
Gaulton A, Bellis LJ, Bento AP. et al. ChEMBL: A large-scale bioactivity database for drug discovery. Nucleic Acids Res 2012; 40(D1): D1100-7.
[http://dx.doi.org/10.1093/nar/gkr777] [PMID: 21948594]
[25]
Bolton E, Wang Y, Thiessen PA, Bryant SH. PubChem: Integrated Platform for Small Molecules and Biological Activities Annual Reports in Computational Chemistry 4. Washington, D.C: American Chemical Society 2008.
[26]
Dallakyan S, Olson AJ. Small-molecule library screening by docking with PyRx Chemical biology. Springer 2015; pp. 243-50.
[27]
Trott O, Olson AJ. AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem 2010; 31(2): 455-61.
[PMID: 19499576]
[28]
Seidel T, Bryant SD, Ibis G, Poli G, Langer T. 3D Pharmacophore Modeling Techniques in Computer‐Aided Molecular Design Using LigandScout. United States: The Wiley Network 2017; pp. 279-309.
[http://dx.doi.org/10.1002/9781119161110.ch20]
[29]
Kassambara A, Kassambara MA. CRAN - Package ggpubr. 2020. Available From: http://cran.nexr.com/web/packages/ggpubr/index.html
[30]
El-Zohairy MA, Zlotos DP, Berger MR, Adwan HH, Mandour YM. Discovery of novel CCR5 ligands as anticolorectal cancer agents by sequential virtual screening. ACS Omega 2021; 6(16): 10921-35.
[http://dx.doi.org/10.1021/acsomega.1c00681] [PMID: 34056245]
[31]
Lipinski CA. Lead- and drug-like compounds: The rule-of-five revolution. Drug Discov Today Technol 2004; 1(4): 337-41.
[http://dx.doi.org/10.1016/j.ddtec.2004.11.007] [PMID: 24981612]
[32]
Moonsamy S, Dash R, Soliman M. Integrated computational tools for identification of CCR5 antagonists as potential HIV-1 entry inhibitors: Homology modeling, virtual screening, molecular dynamics simulations and 3D QSAR analysis. Molecules 2014; 19(4): 5243-65.
[http://dx.doi.org/10.3390/molecules19045243] [PMID: 24762964]
[33]
Abrol R, Trzaskowski B, Goddard WA III, Nesterov A, Olave I, Irons C. Ligand- and mutation-induced conformational selection in the CCR5 chemokine G protein-coupled receptor. Proc Natl Acad Sci USA 2014; 111(36): 13040-5.
[http://dx.doi.org/10.1073/pnas.1413216111] [PMID: 25157173]
[34]
Lin HY, Ho Y, Liu HL. Structure-based pharmacophore modeling to discover novel CCR5 inhibitors for HIV-1/cancers therapy. J Biomed Sci Eng 2019; 12(1): 10-30.
[http://dx.doi.org/10.4236/jbise.2019.121002]
[35]
Taylor CA, Miller BR III, Parish CA. Design and computational support for the binding stability of a new CCR5/CXCR4 dual tropic inhibitor. J Mol Graph Model 2017; 75: 71-9.
[http://dx.doi.org/10.1016/j.jmgm.2017.02.012] [PMID: 28575798]
[36]
Garcia-Perez J, Rueda P, Alcami J. et al. Allosteric model of maraviroc binding to CC chemokine receptor 5 (CCR5). J Biol Chem 2011; 286(38): 33409-21.
[http://dx.doi.org/10.1074/jbc.M111.279596] [PMID: 21775441]
[37]
Nakata H, Maeda K, Das D. et al. Activity and structural analysis of GRL-117C: A novel small molecule CCR5 inhibitor active against R5-tropic HIV-1s. Sci Rep 2019; 9(1): 4828.
[http://dx.doi.org/10.1038/s41598-019-41080-w] [PMID: 30886166]
[38]
Arnatt CK, Zaidi SA, Zhang Z. et al. Design, syntheses, and characterization of pharmacophore based chemokine receptor CCR5 antagonists as anti prostate cancer agents. Eur J Med Chem 2013; 69: 647-58.
[http://dx.doi.org/10.1016/j.ejmech.2013.09.004] [PMID: 24095757]
[39]
Thakuria R, Nath NK, Saha BK. The nature and applications of π–π interactions: A perspective. Cryst Growth Des 2019; 19(2): 523-8.
[http://dx.doi.org/10.1021/acs.cgd.8b01630]
[40]
Ringer AL, Sinnokrot MO, Lively RP, Sherrill CD. The effect of multiple substituents on sandwich and T-shaped π-π interactions. Chemistry 2006; 12(14): 3821-8.
[http://dx.doi.org/10.1002/chem.200501316] [PMID: 16514687]
[41]
Wheeler SE. Local nature of substituent effects in stacking interactions. J Am Chem Soc 2011; 133(26): 10262-74.
[http://dx.doi.org/10.1021/ja202932e] [PMID: 21599009]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy